As on Wednesday, Viracta Therapeutics Inc (NASDAQ: VIRX) got off with the flyer as it spiked 3.72% to $0.15, before settling in for the price of $0.14 at the close. Taking a more long-term approach, VIRX posted a 52-week range of $0.13-$1.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 134.94% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 44.96%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 31.57%. This publicly-traded company’s shares outstanding now amounts to $39.09 million, simultaneously with a float of $27.94 million. The organization now has a market capitalization sitting at $6.10 million. At the time of writing, stock’s 50-day Moving Average stood at $0.2051, while the 200-day Moving Average is $0.5455.
Viracta Therapeutics Inc (VIRX) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Viracta Therapeutics Inc’s current insider ownership accounts for 29.69%, in contrast to 13.00% institutional ownership. According to the most recent insider trade that took place on Feb 27 ’24, this organization’s CFO and COO sold 3,405 shares at the rate of 0.73, making the entire transaction reach 2,493 in total value, affecting insider ownership by 102,306. Preceding that transaction, on Nov 30 ’23, Company’s President and CEO bought 52,094 for 0.49, making the whole transaction’s value amount to 25,734. This particular insider is now the holder of 52,094 in total.
Viracta Therapeutics Inc (VIRX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Viracta Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 31.57% and is forecasted to reach -0.51 in the upcoming year.
Viracta Therapeutics Inc (NASDAQ: VIRX) Trading Performance Indicators
Let’s observe the current performance indicators for Viracta Therapeutics Inc (VIRX). It’s Quick Ratio in the last reported quarter now stands at 0.76. The Stock has managed to achieve an average true range (ATR) of 0.02.
In the same vein, VIRX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.10, a figure that is expected to reach -0.19 in the next quarter, and analysts are predicting that it will be -0.51 at the market close of one year from today.
Technical Analysis of Viracta Therapeutics Inc (VIRX)
Through scrutinizing the latest numbers posted by the [Viracta Therapeutics Inc, VIRX], it can be observed that its last 5-days Average volume of 0.54 million was better the volume of 0.5 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 42.21% While, its Average True Range was 0.0166.
Raw Stochastic average of Viracta Therapeutics Inc (VIRX) in the period of the previous 100 days is set at 3.66%, which indicates a major fall in contrast to 29.39% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 68.71% that was lower than 79.02% volatility it exhibited in the past 100-days period.
